Use of darunavir/ritonavir once daily in treatment-naive pregnant woman: Pharmacokinetics, compartmental exposure, efficacy and safety

AIDS

Volumn 24, Issue 7, 2010, Pages 1083-1084

  Ivanovic, Jelena ^a   Bellagamba, Rita ^a   Nicastri, Emanuele ^a   Signore, Fabrizio ^b   Vallone, Cristina ^b   Tempestilli, Massimo ^a   Tommasi, Chiara ^a   Mazzitelli, Luisa ^a   Narciso, Pasquale ^a  

^a Lazzaro Spallanzani   (Italy)

^b SAN CAMILLO FORLANINI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; DARUNAVIR; EFAVIRENZ; EMTRICITABINE; LOPINAVIR; RITONAVIR; TENOFOVIR; ZIDOVUDINE;

ADULT; CASE REPORT; DIARRHEA; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; PREGNANCY; PRIORITY JOURNAL; THIRD TRIMESTER PREGNANCY;

ADULT; CD4 LYMPHOCYTE COUNT; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INFANT, NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RITONAVIR; SULFONAMIDES; TREATMENT OUTCOME; VIRAL LOAD;

EID: 77950959953     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32833653b2     Document Type: Letter

References (15)

1. Kosel BW, Beckerman KP, Hayashi S, Homma M, Aweeka FT. Pharmacokinetics of nelfinavir and indinavir in HIV-1-infected pregnant women. AIDS 2003; 17:1195-1199.
2. Nellen JF, Schillevoort I, Wit FW, Bergshoeff AS, Godfried MH, Boer K, et al. Nelfinavir plasma concentrations are low during pregnancy. Clin Infect Dis 2004; 39:736-740.
3. Acosta EP, Bardeguez A, Zorrilla CD, Van Dyke R, Hughes MD, Huang S, et al. Pediatric AIDS Clinical Trials Group 386 Protocol Team. Pharmacokinetics of saquinavir plus low-dose ritonavir in human immunodeficiency virus-infected pregnant women. Antimicrob Agents Chemother 2004; 48: 430-436.
4. Stek AM, Mirochnick M, Capparelli E, Best BM, Hu C, Burchett SK, et al. Reduced lopinavir exposure during pregnancy. AIDS 2006; 20:1931-1939.
5. Pacanowski J, Bollens D, Poirier JM, Morand-Joubert L, Cas-taigne V, Girard PM, et al. Efficacy of darunavir despite low plasma trough levels during late pregnancy in an HIV-hepatitis C virus infected patient. AIDS 2009; 23:1923-1930.
6. Marzolini C, Rudin C, Decosterd LA, Telenti A, Schreyer A, Biollaz J, et al., Swiss Mother\+ Child HIV Cohort study. Transplacental passage of protease inhibitors at delivery. AIDS 2002; 16:889-893.
7. Mirochnick M, Dorenbaum A, Holland D, Cunningham-Schra-der B, Cunningham C, Gelber R, et al. Concentration of protease inhibitors in cord-blood following in utero exposure. Pediatr Infect Dis J 2002; 21:835-838.
8. Gingelmaier A, Kurowski M, Kästner R, Eberle J, Mylonas I, Belohradsky BH, et al. Placental transfer and pharmacokinetics of lopinavir and other protease inhibitors in combination with nevirapine at delivery. AIDS 2006; 20:1737-1743.
9. Ripamonti D, Cattaneo D, Maggiolo F, Airoldi M, Frigerio L, Bertuletti P, et al. Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer. AIDS 2007; 21:2409-2415.
10. Bryson YJ, Mirochnick M, Stek A, Mofenson LM, Connor J, Capparelli E, et al., PACTG 353 Team. Pharmacokinetics and safety of nelfinavir when used in combination with zidovudine and lamivudine in HIV-infected pregnant women: Pediatric AIDS Clinical Trials Group (PACTG) Protocol 353. HIV Clin Trials 2008; 9:115-125.
11. Sued O, Lattner J, Gun A, Patterson P, Abusamra L, Cesar C, et al. Use of darunavir and enfuvirtide in a pregnant woman. Int J STD AIDS 2008; 19:866-867.
12. Furco A, Gosrani B, Nicholas S, Williams A, Braithwaite W, Pozniak A, et al. Successful use of darunavir, etravirine, en-fuvirtide and tenofovir/emtricitabine in pregnant woman with multiclass HIV resistance. AIDS 2009; 23:434-435.
13. Ripamonti D, Cattaneo D, Cortinovis M, Maggiolo F, Suter F. Transplacental passage of ritonavir-boosted darunavir in two pregnant women. Int J STD AIDS 2009; 20:215-216.
14. D'Avolio A, Baietto L, Siccardi M, Sciandra M, Simiele M, Oddone V, et al. An HPLC-PDA method for the simultaneous quantification of the HIV integrase inhibitor raltegravir, the new nonnucleoside reverse transcriptase inhibitor etravirine, and 11 other antiretroviral agents in the plasma of HIV-in-fected patients. Ther Drug Monit 2008; 30:662-669.
15. Boffito M, Miralles D, Hill A. Pharmacokinetics, efficacy, and safety of darunavir/ritonavir 800/100 mg once-daily in treat-ment-nä?ve and-experienced patients. HIV Clin Trials 2008; 9:418-427